EGFR and non-small cell lung carcinoma: This gatekeeper mutation of EGFR occurs in 50%–60% of patients with NSCLC who have EGFR activating mutations and who acquire resistance to first and second generation EGFR tyrosine kinase inhibitors (EGFR‐TKI).5, 6